Behavioral interventions in multiple sclerosis: A biopsychosocial perspective

Expert Review of Neurotherapeutics

Volumn 12, Issue 9, 2012, Pages 1089-1100

  Heesen, C ^a   Kopke S ^b   Kasper, J ^a   Poettgen, J ^a   Tallner, A ^c   Mohr, D C ^d   Gold, S M ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

behavioral interventions; childhood trauma; cognitive behavioral therapy; exercise; mindfulness; psychoneuroimmunology; self management; stress response systems

Indexed keywords

BETA INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; GLATIRAMER; NATALIZUMAB;

CELL PROLIFERATION; CHRONIC DISEASE; COGNITIVE DEFECT; COGNITIVE THERAPY; CROSS-SECTIONAL STUDY; DECISION MAKING; DEPRESSION; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; EXERCISE; FATIGUE; GERMANY; HEALTH CARE DELIVERY; HEALTH PROMOTION; HEALTH STATUS; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFLAMMATION; INTERVENTION STUDY; LEARNING; LIFE STRESS; MEMORY; META ANALYSIS (TOPIC); MOTOR PERFORMANCE; MULTIPLE SCLEROSIS; PATIENT EDUCATION; PATIENT INFORMATION; PERINATAL PERIOD; PHYSICAL ACTIVITY; PSYCHOSOCIAL CARE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RISK FACTOR; SEXUAL ABUSE; STRESS MANAGEMENT;

ANIMALS; BEHAVIOR, ANIMAL; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DEPRESSION; EVIDENCE-BASED MEDICINE; EXERCISE; HUMANS; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; SOCIAL SUPPORT; SPORTS;

EID: 84867322331     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.103     Document Type: Review

References (105)

1. Kesselring J. Multiple Sklerose. Kohlhammer, Stuttgart, Köln, Berlin (1989).
2. Rudick RA, Miller AE. Multiple sclerosis or multiple possibilities: the continuing problem of misdiagnosis. Neurology 78(24), 1904-1906 (2012).
3. Aktas O, Kieseier B, Hartung HP. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci. 33(3), 140-152 (2010).
4. Bruce JM, Hancock LM, Arnett P, Lynch S. Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. J. Behav. Med. 33(3), 219-227 (2010).
5. Mishel MH. Reconceptualization of the uncertainty in illness theory. Image. J. Nurs. Sch. 22(4), 256-262 (1990).
6. Fischer A, Heesen C, Gold SM. Biological outcome measurements for behavioral interventions in multiple sclerosis. Ther. Adv. Neurol. Disord. 4(4), 217-229 (2011).
7. Li J, Johansen C, Broønnum-Hansen H, Stenager E, Koch-Henriksen N, Olsen J. The risk of multiple sclerosis in bereaved parents: a nationwide cohort study in Denmark. Neurology 62(5), 726-729 (2004).
8. Lupien SJ, McEwen BS, Gunnar MR, Heim C. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat. Rev. Neurosci. 10(6), 434-445 (2009).
9. Riise T, Mohr DC, Munger KL, Rich-Edwards JW, Kawachi I, Ascherio A. Stress and the risk of multiple sclerosis. Neurology 76(22), 1866-1871 (2011).
10. Spitzer C, Bouchain M, Winkler LY et al. Childhood trauma in multiple sclerosis: a case-control study. Psychosom. Med. 74(3), 312-318 (2012).
11. Charcot JM. Lectures on the Diseases of the Nervous System. New Sydenham Society, London, UK (1877).
12. Artemiadis AK, Anagnostouli MC, Alexopoulos EC. Stress as a risk factor for multiple sclerosis onset or relapse: a systematic review. Neuroepidemiology 36(2), 109-120 (2011).
13. Mohr DC, Goodkin DE, Bacchetti P et al. Psychological stress and the subsequent appearance of new brain MRI lesions in MS. Neurology 55(1), 55-61 (2000).
14. Golan D, Somer E, Dishon S, Cuzin-Disegni L, Miller A. Impact of exposure to war stress on exacerbations of multiple sclerosis. Ann. Neurol. 64(2), 143-148 (2008).
15. Yamout B, Itani S, Hourany R, Sibaii AM, Yaghi S. The effect of war stress on multiple sclerosis exacerbations and radiological disease activity. J. Neurol. Sci. 288(1-2), 42-44 (2010).
16. Patten SB, Beck CA, Williams JV, Barbui C, Metz LM. Major depression in multiple sclerosis: a population-based perspective. Neurology 61(11), 1524-1527 (2003).
17. Feinstein A. Multiple sclerosis and depression. Mult. Scler. 17(11), 1276-1281 (2011).
18. Julian LJ, Vella L, Vollmer T, Hadjimichael O, Mohr DC. Employment in multiple sclerosis. Exiting and re-entering the work force. J. Neurol. 255(9), 1354-1360 (2008).
19. Feuillet L, Reuter F, Audoin B et al. Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult. Scler. 13(1), 124-127 (2007).
20. Filippi M, Rocca MA, Benedict RH et al. The contribution of MRI in assessing cognitive impairment in multiple sclerosis. Neurology 75(23), 2121-2128 (2010).
21. Henry A, Tourbah A, Chaunu MP, Rumbach L, Montreuil M, Bakchine S. Social cognition impairments in relapsingremitting multiple sclerosis. J. Int. Neuropsychol. Soc. 17(6), 1122-1131 (2011).
22. Mohr DC, Genain C. Social support as a buffer in the relationship between treatment for depression and T-cell production of interferon-? in patients with multiple sclerosis. J. Psychosom. Res. 57(2), 155-158 (2004).
23. Ehrensperger MM, Grether A, Romer G et al. Neuropsychological dysfunction, depression, physical disability, and coping processes in families with a parent affected by multiple sclerosis. Mult. Scler. 14(8), 1106-1112 (2008).
24. Ebers GC, Traboulsee A, Li D et al; Investigators of the 16-year long-term follow-up study. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFN?-1b trial. J. Neurol. Neurosurg. Psychiatr. 81(8), 907-912 (2010).
25. Heesen C, Kleiter I, Nguyen F et al. Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists. Mult. Scler. 16(12), 1507-1512 (2010).
26. Fischer JS, Priore RL, Jacobs LD et al. Neuropsychological effects of interferon ?-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann. Neurol. 48(6), 885-892 (2000).
27. Benedict RH, Zivadinov R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat. Rev. Neurol. 7(6), 332-342 (2011).
28. Koch MW, Glazenborg A, Uyttenboogaart M, Mostert J, De Keyser J. Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database Syst. Rev. 2, CD007295 (2011).
29. Plow MA, Finlayson M, Rezac M. A scoping review of self-management interventions for adults with multiple sclerosis. PM R 3(3), 251-262 (2011).
30. Lejbkowicz I, Caspi O, Miller A. Participatory medicine and patient empowerment towards personalized healthcare in multiple sclerosis. Expert Rev. Neurother. 12(3), 343-352 (2012).
31. Bunge M, Mühlhauser I, Steckelberg A. What constitutes evidence-based patient information? Overview of discussed criteria. Patient Educ. Couns. 78(3), 316-328 (2010).
32. Hawe P, Shiell A, Riley T. Complex interventions: how 'out of control' can a randomised controlled trial be? BMJ 328(7455), 1561-1563 (2004).
33. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M; Medical Research Council Guidance. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ 337, a1655 (2008).
34. Motl RW, Gosney JL. Effect of exercise training on quality of life in multiple sclerosis: a meta-analysis. Mult. Scler. 14(1), 129-135 (2008).
35. Asano M, Dawes DJ, Arafah A, Moriello C, Mayo NE. What does a structured review of the effectiveness of exercise interventions for persons with multiple sclerosis tell us about the challenges of designing trials? Mult. Scler. 15(4), 412-421 (2009).
36. Dalgas U, Stenager E, Jakobsen J et al. Resistance training improves muscle strength and functional capacity in multiple sclerosis. Neurology 73(18), 1478-1484 (2009).
37. Tallner A, Waschbisch A, Wenny I et al. Multiple sclerosis relapses are not associated with exercise. Mult. Scler. 18(2), 232-235 (2012).
38. Schulz KH, Gold SM, Witte J et al. Impact of aerobic training on immune-endocrine parameters, neurotrophic factors, quality of life and coordinative function in multiple sclerosis. J. Neurol. Sci. 225(1-2), 11-18 (2004).
39. Snook EM, Motl RW. Effect of exercise training on walking mobility in multiple sclerosis: a meta-analysis. Neurorehabil. Neural Repair 23(2), 108-116 (2009).
40. Andreasen AK, Stenager E, Dalgas U. The effect of exercise therapy on fatigue in multiple sclerosis. Mult. Scler. 17(9), 1041-1054 (2011).
41. Dalgas U, Stenager E. Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis? Ther. Adv. Neurol. Disord. 5(2), 81-95 (2012).
42. Hillman CH, Erickson KI, Kramer AF. Be smart, exercise your heart: exercise effects on brain and cognition. Nat. Rev. Neurosci. 9(1), 58-65 (2008).
43. Smith PJ, Blumenthal JA, Hoffman BM et al. Aerobic exercise and neurocognitive performance: a meta-analytic review of randomized controlled trials. Psychosom. Med. 72(3), 239-252 (2010).
44. Motl RW, Sandroff BM, Benedict RH. Cognitive dysfunction and multiple sclerosis: developing a rationale for considering the efficacy of exercise training. Mult. Scler. 17(9), 1034-1040 (2011).
45. Oken BS, Kishiyama S, Zajdel D et al. Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology 62(11), 2058-2064 (2004).
46. Prakash RS, Patterson B, Janssen A, Abduljalil A, Boster A. Physical activity associated with increased resting-state functional connectivity in multiple sclerosis. J. Int. Neuropsychol. Soc. 17(6), 986-997 (2011).
47. Prakash RS, Snook EM, Motl RW, Kramer AF. Aerobic fitness is associated with gray matter volume and white matter integrity in multiple sclerosis. Brain Res. 1341, 41-51 (2010).
48. Rietberg MB, Brooks D, Uitdehaag BM, Kwakkel G. Exercise therapy for multiple sclerosis. Cochrane Database Syst. Rev. 1, CD003980 (2005).
49. Rasova K, Feys P, Henze T et al. Emerging evidence-based physical rehabilitation for multiple sclerosis-towards an inventory of current content across Europe. Health Qual. Life Outcomes 8, 76 (2010).
50. Motl RW, Dlugonski D, Wójcicki TR, McAuley E, Mohr DC. Internet intervention for increasing physical activity in persons with multiple sclerosis. Mult. Scler. 17(1), 116-128 (2011).
51. Coulter A. Evidence based patient information is important, so there needs to be a national strategy to ensure it. BMJ 317(7153), 225-226 (1998).
52. Stacey D, Bennett CL, Barry MJ et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst. Rev. 10, CD001431 (2011).
53. Stacey D, Kryworuchko J, Bennett C, Murray MA, Mullan S, Légaré F. Decision coaching to prepare patients for making health decisions: a systematic review of decision coaching in trials of patient decision AIDS. Med. Decis. Making 32(3), E22-E33 (2012).
54. Coulter A, Ellins J. Effectiveness of strategies for informing, educating, and involving patients. BMJ 335(7609), 24-27 (2007).
55. Heesen C, Schulz KH, Fiehler J et al. Correlates of cognitive dysfunction in multiple sclerosis. Brain Behav. Immun. 24(7), 1148-1155 (2010).
56. Köpke S, Solari A, Khan F, Heesen C, Giordano A. Information provision for persons with multiple sclerosis (protocol). Cochrane Database Syst. Rev. 10, CD008757 (2010).
57. Ennis M, Thain J, Boggild M, Baker GA, Young CA. A randomized controlled trial of a health promotion education programme for people with multiple sclerosis. Clin. Rehabil. 20(9), 783-792 (2006).
58. Kasper J, Heesen C, Mühlhauser I. Evidence-based patient information: the example of immunotherapy for patients with multiple sclerosis. Bundesgesundheitsblatt. Gesundheitsforschung. Gesundheitsschutz 52(1), 77-85 (2009).
59. Köpke S, Kasper J, Mühlhauser I, Nübling M, Heesen C. Patient education program to enhance decision autonomy in multiple sclerosis relapse management: a randomized-controlled trial. Mult. Scler. 15(1), 96-104 (2009).
60. O'Hara L, Cadbury H, De SL, Ide L. Evaluation of the effectiveness of professionally guided self-care for people with multiple sclerosis living in the community: a randomized controlled trial. Clin. Rehabil. 16(2), 119-128 (2002).
61. Solari A, Martinelli V, Trojano M et al; SIMS-Trial group. An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. Mult. Scler. 16(11), 1393-1405 (2010).
62. Beck AT, Rush AJ, Shaw B, Emery G. Cognitive Therapy of Depression. Guilford, NY, USA (1979).
63. Mohr DC. The Stress and Mood Management Program for Individuals with Multiple Sclerosis: Therapist Guide. Oxford Press, NY, USA (2010).
64. Thomas PW, Thomas S, Hillier C, Galvin K, Baker R. Psychological interventions for multiple sclerosis. Cochrane Database Syst. Rev. 1, CD004431 (2006).
65. Dennison L, Moss-Morris R. Cognitive-behavioral therapy: what benefits can it offer people with multiple sclerosis? Expert Rev. Neurother. 10(9), 1383-1390 (2010).
66. Grossman P, Kappos L, Gensicke H et al. MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology 75(13), 1141-1149 (2010).
67. Mohr DC, Lovera J, Brown T et al. A randomized trial of stress management for the prevention of new brain lesions in MS. Neurology 79(5), 412-419 (2012).
68. van Kessel K, Moss-Morris R, Willoughby E, Chalder T, Johnson MH, Robinson E. A randomized controlled trial of cognitive behavior therapy for multiple sclerosis fatigue. Psychosom. Med. 70(2), 205-213 (2008).
69. Harrison V, Proudfoot J, Wee PP, Parker G, Pavlovic DH, Manicavasagar V. Mobile mental health: review of the emerging field and proof of concept study. J. Ment. Health 20(6), 509-524 (2011).
70. Kabat-Zinn J, Massion AO, Kristeller J et al. Effectiveness of a meditation-based stress reduction program in the treatment of anxiety disorders. Am. J. Psychiatry 149(7), 936-943 (1992).
71. Mohr DC, Burke H, Beckner V, Merluzzi N. A preliminary report on a skills-based telephone-administered peer support programme for patients with multiple sclerosis. Mult. Scler. 11(2), 222-226 (2005).
72. Mohr DC, Cox D, Merluzzi N. Selfinjection anxiety training: a treatment for patients unable to self-inject injectable medications. Mult. Scler. 11(2), 182-185 (2005).
73. Mohr DC, Epstein L, Luks TL et al. Brain lesion volume and neuropsychological function predict efficacy of treatment for depression in multiple sclerosis. J. Consult. Clin. Psychol. 71(6), 1017-1024 (2003).
74. Messmer Uccelli M, Mancuso Mohr L, Battaglia MA, Zagami P, Mohr DC. Peer support groups in multiple sclerosis: current effectiveness and future directions. Mult. Scler. 10(1), 80-84 (2004).
75. das Nair R, Ferguson H, Stark DL, Lincoln NB. Memory rehabilitation for people with multiple sclerosis. Cochrane Database Syst. Rev. 3, CD008754 (2012).
76. Rosti-Otajärvi EM, Hämäläinen PI. Neuropsychological rehabilitation for multiple sclerosis. Cochrane Database Syst. Rev. 11, CD009131 (2011).
77. Gold SM, Mohr DC, Huitinga I, Flachenecker P, Sternberg EM, Heesen C. The role of stress-response systems for the pathogenesis and progression of MS. Trends Immunol. 26(12), 644-652 (2005).
78. Wüst S, van den Brandt J, Tischner D et al. Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J. Immunol. 180(12), 8434-8443 (2008).
79. van den Brandt J, Lühder F, McPherson KG et al. Enhanced glucocorticoid receptor signaling in T cells impacts thymocyte apoptosis and adaptive immune responses. Am. J. Pathol. 170(3), 1041-1053 (2007).
80. Gold SM, Sasidhar MV, Lagishetty V et al. Dynamic development of glucocorticoid resistance during autoimmune neuroinflammation. J. Clin. Endocrinol. Metab. doi:10.1210/jc.2012-1294 (2012) (Epub ahead of print).
81. Miller GE, Chen E. Life stress and diminished expression of genes encoding glucocorticoid receptor and beta2-adrenergic receptor in children with asthma. Proc. Natl Acad. Sci. USA 103(14), 5496-5501 (2006).
82. Stark JL, Avitsur R, Padgett DA, Campbell KA, Beck FM, Sheridan JF. Social stress induces glucocorticoid resistance in macrophages. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280(6), R1799-R1805 (2001).
83. Quan N, Avitsur R, Stark JL et al. Molecular mechanisms of glucocorticoid resistance in splenocytes of socially stressed male mice. J. Neuroimmunol. 137(1-2), 51-58 (2003).
84. Ziemssen T. Multiple sclerosis beyond EDSS: depression and fatigue. J. Neurol. Sci. 277(Suppl. 1), S37-S41 (2009).
85. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 7(12), 1139-1151 (2008).
86. Mohr DC, Goodkin DE, Islar J, Hauser SL, Genain CP. Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis. Arch. Neurol. 58(7), 1081-1086 (2001).
87. Luders E, Clark K, Narr KL, Toga AW. Enhanced brain connectivity in long-term meditation practitioners. Neuroimage 57(4), 1308-1316 (2011).
88. Luders E, Kurth F, Mayer EA, Toga AW, Narr KL, Gaser C. The unique brain anatomy of meditation practitioners: alterations in cortical gyrification. Front. Hum. Neurosci. 6, 34 (2012).
89. Luders E, Phillips OR, Clark K, Kurth F, Toga AW, Narr KL. Bridging the hemispheres in meditation: thicker callosal regions and enhanced fractional anisotropy (FA) in long-term practitioners. Neuroimage 61(1), 181-187 (2012).
90. Luders E, Toga AW, Lepore N, Gaser C. The underlying anatomical correlates of long-term meditation: larger hippocampal and frontal volumes of gray matter. Neuroimage 45(3), 672-678 (2009).
91. Hölzel BK, Ott U, Gard T et al. Investigation of mindfulness meditation practitioners with voxel-based morphometry. Soc. Cogn. Affect. Neurosci. 3(1), 55-61 (2008).
92. Sicotte NL, Kern KC, Giesser BS et al. Regional hippocampal atrophy in multiple sclerosis. Brain 131(Pt 4), 1134-1141 (2008).
93. Gold SM, Kern KC, O'Connor MF et al. Smaller cornu ammonis (CA) 2-3 / dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms. Biol. Psychiatry 68(6), 553-559 (2010).
94. Kiy G, Lehmann P, Hahn HK, Eling P, Kastrup A, Hildebrandt H. Decreased hippocampal volume, indirectly measured, is associated with depressive symptoms and consolidation deficits in multiple sclerosis. Mult. Scler. 17(9), 1088-1097 (2011).
95. Pedersen BK. Exercise-induced myokines and their role in chronic diseases. Brain Behav. Immun. 25(5), 811-816 (2011).
96. Cotman CW, Berchtold NC, Christie LA. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci. 30(9), 464-472 (2007).
97. Gold SM, Schulz KH, Hartmann S et al. Basal serum levels and reactivity of nerve growth factor and brain-derived neurotrophic factor to standardized acute exercise in multiple sclerosis and controls. J. Neuroimmunol. 138(1-2), 99-105 (2003).
98. Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat. Rev. Immunol. 11(9), 607-615 (2011).
99. Petajan JH, Gappmaier E, White AT, Spencer MK, Mino L, Hicks RW. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann. Neurol. 39(4), 432-441 (1996).
100. Romberg A, Virtanen A, Ruutiainen J et al. Effects of a 6-month exercise program on patients with multiple sclerosis: a randomized study. Neurology 63(11), 2034-2038 (2004).
101. Schwartz CE. Teaching coping skills enhances quality of life more than peer support: results of a randomized trial with multiple sclerosis patients. Health Psychol. 18(3), 211-220 (1999).
102. Lincoln NB, Dent A, Harding J et al. Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis. J. Neurol. Neurosurg. Psychiatr. 72(1), 93-98 (2002).
103. Stuifbergen AK, Becker H, Blozis S, Timmerman G, Kullberg V. A randomized clinical trial of a wellness intervention for women with multiple sclerosis. Arch. Phys. Med. Rehabil. 84(4), 467-476 (2003).
104. Rigby S. Coping With MS. University of Liverpool, Liverpool, UK (2003).
105. Mathiowetz VG, Finlayson ML, Matuska KM, Chen HY, Luo P. Randomized controlled trial of an energy conservation course for persons with multiple sclerosis. Mult. Scler. 11(5), 592-601 (2005).